Nvidia's landmark plan to invest up to $100 billion in OpenAI has stalled, with executives questioning the deal's structure and OpenAI's financial discipline amid a fiercely competitive AI landscape.
Ford Motor Company and Chinese tech giant Xiaomi have both denied a Financial Times report claiming preliminary discussions about producing Xiaomi's electric vehicles in the United States, as the auto industry navigates steep new tariffs on Chinese imports.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
The Qatar Investment Authority has backed a new $200 million fund by Shorooq Partners, aiming to inject institutional capital into the region's mature startups and bridge a critical funding hurdle on the path to public listings.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.
A landmark tripartite agreement between financial heavyweight Schroders, battery leader CATL, and investment firm Lochpine Capital aims to deploy up to 10GWh of energy storage across Europe, marking a significant step in the continent's clean energy transition.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
A landmark investment proposal between AI titans Nvidia and OpenAI has stalled, with both companies reassessing terms amid internal concerns and a shifting competitive landscape, according to a Wall Street Journal report.
The ninth edition of the Istanbul Fashion Connection (IFCO) is poised to gather an estimated 30,000 trade visitors and 400 exhibitors this February, highlighting Turkey's expanding influence in the global apparel sourcing landscape.
French reinsurer SCOR has expanded its underwriting capacity for Baobab Insurance's cyber policies in Germany and Austria, now covering companies with annual revenues up to €1 billion, marking a strategic push into Europe's industrial cyber risk market.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
Following a significant pullback, NetEase (SEHK: 9999) shares are trading at levels that some analysts deem undervalued. We examine the financial models, peer comparisons, and the broader sector headwinds facing the Chinese gaming giant to assess if the current price presents a strategic entry point for long-term investors.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.
While the sub-$10 stock universe offers potential for significant returns, it demands rigorous scrutiny. We analyze one company with a compelling growth thesis and two others where investors should proceed with caution.
